VIFOR-PHARMA
10.12.2021 17:47:07 CET | Business Wire | Press release
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease. Vamifeport, developed by Vifor Pharma, is a novel oral ferroportin inhibitor investigated for treatment of diseases characterized by ineffective production of red blood cells and iron overload, including SCD and beta-thalassemia. It has been granted orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of SCD.
Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented, “Starting the phase-IIa trial is an important milestone in the clinical development of vamifeport for sickle cell disease, a debilitating orphan condition for which there are very limited treatment options. Patients worldwide continue to suffer from consequences of the disease which dramatically impacts their quality of life and life expectancy. We look forward to continuing development of our potential new treatment for these patients”.
SCD is a group of inherited red blood cell disorders and is a genetic condition present at birth. In this disease, red blood cells carry abnormal haemoglobin, which makes them prone to rupture, causing adhesion of sickle cells and inflammatory cells to the blood vessels. This ultimately leads to an obstruction of blood flow and organ damage. There are an estimated 150,000 patients in Europe and the US combined living with sickle cell disease.
About the SCD-202 trial
The phase-IIa study is a randomized, double-blind, placebo-controlled, parallel group trial aiming to recruit 25 patients at 14 clinical sites in the United States, the United Kingdom, Lebanon and Greece. The primary objective of the trial is to assess the change in markers of hemolysis (the rupturing of red blood cells) upon treatment with vamifeport. Patients will undergo initial treatment for 4 weeks, followed by an additional 4-week period with either maintenance of the dose level or a dose step-up. The study also includes a 4-week follow-up period after treatment. End of enrolment is expected mid-2022 with topline results anticipated at the end of 2022.
Further information about the study, including eligibility requirements, is available at www.clinicaltrials.gov (NTC04817670).
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About vamifeport
Vamifeport is an oral inhibitor of ferroportin, an enzyme essential for the body’s transport of iron and plays a key role in regulating iron uptake and distribution in the body. Vamifeport binds to ferroportin and blocks it to prevent excessive iron release into the blood. As iron is needed for the formation of haemoglobin, this relative decrease in iron availability is expected to reduce the concentration of abnormal haemoglobin in red blood cells and prevent ensuing unfavorable events. Vamifeport-mediated ferroportin inhibition may lead to less haemolysis, decrease of inflammation and better blood flow with consequent improvement of both the symptoms and clinical outcomes of SCD.
Vamifeport is currently also in phase II development for beta-thalassemia, an inherited rare blood disorder that reduces the production of functional haemoglobin in red blood cells, which can lead to a lack of oxygen in many parts of the body and potentially cause anaemia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005374/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Makes NSC Safety Congress & Expo Debut10.9.2026 19:45:00 CEST | Press release
Highlights Innovative Fibers That Enhance Worker Comfort, Performance, and Protection The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, today announced its inaugural exhibition at the NSC Safety Congress & Expo, being held September 14-16 in Indianapolis. The company also marks the North American debut of its “FIBERS THATWORK” portfolio of innovative solutions for workwear, uniforms, and protective apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910402207/en/ The LYCRA Company will debut its FIBERS THAT WORK portfolio at the NSC Safety Congress & Expo in Indianapolis, highlighting fiber technologies engineered to enhance comfort, durability, visibility, and protection in workwear and protective apparel. "Comfort is fundamental to workwear performance," said Tara Maurer-Mackay, product category director, branded specialty products at The LY
Turning Up the Heat: ProAmpac Helps Power Circle K’s Flamin’ Hot® Boneless Chicken Wings Launch10.9.2026 18:12:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, is proud to announce its role in supporting Circle K's launch of Flamin' Hot® Boneless Chicken Wings, created in partnership with PepsiCo/Frito-Lay. Designed to address key challenges in hot food packaging, ProAmpac's custom fiber-based tray helps maintain food quality, improve shelf appeal, and enhance the consumer experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910495607/en/ Flamin' Hot Chicken Bites Circle K sought a better way to merchandise its Flamin’ Hot® Boneless Chicken Wings while addressing several performance challenges, including heat retention, moisture loss, and grease resistance, while extending hot hold time. ProAmpac responded with a custom tray designed specifically for the recipe and portion size, demonstrating its flexibility in meeting unique customer design and performance requirements. Working from PepsiCo’s initial br
Record Currency Management wins new FX Alpha and Frontier Market mandates10.9.2026 17:30:00 CEST | Press release
Record Currency Management Ltd (RCM), a subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce that it has been awarded two new mandates of strategic importance – an FX Alpha mandate and an FX Frontier mandate. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing over USD 122 billion of assets on behalf of institutional clients worldwide. Record’s client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. For institutional investors, currency can represent both a source of risk and a potential source of differentiated returns. Live since 2012, Record’s FX Alpha strategy aims to deliver attractive risk-adjusted returns without cap
Azizi Developments Introduces USD 8.1 Billion Master-Planned Community Azizi Florence in Sharjah10.9.2026 16:08:00 CEST | Press release
Azizi Developments, a leading private developer in the UAE, is unveiling Azizi Florence, a USD 8.1 billion master-planned community marking its first project in Sharjah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910091949/en/ Azizi Florence (Photo: AETOSWire) The freehold development will feature 1,130 villas, more than 6,000 townhouses and 3,500 apartments, with three-bedroom townhouses starting from USD 515,000 at USD 231 per square foot of sellable area. Designed as an integrated destination, Azizi Florence will bring together residential, retail, hospitality, education, leisure and wellness offerings, centred around a 1.7-million-square-foot Central Park. Six residential clusters will each feature a park, clubhouse, community centre and landscaped gardens. Mr. Mirwais Azizi, Founder and Chairman of Azizi Group, said: “Returning to Sharjah after more than three decades is deeply meaningful to me, as this emirate w
Agentic Crypto Payments Have Surged by 500%1 in the Last Three Months, Crypto Compliance Must Become Agentic Too10.9.2026 15:53:00 CEST | Press release
Elliptic is publishing eight principles for governing agentic on-chain risk: the Elliptic Standard Elliptic,the global leader in on-chain risk, today published the Elliptic Standard: eight principles for governing agentic on-chain risk. Elliptic has been at the intersection of financial crime and on-chain finance since 2013, long enough to recognize the shift to agentic transactions as a defining inflection point in financial crime risk, and to be the first to define what governing it demands. On-chain finance is now running at agentic speed. Machines are originating, authorizing and settling transactions at a volume no human team can review. Illicit actors are using AI to evade detection at a speed and volume that manual processes cannot track. Models built around human review were never designed for this world. They are already overwhelmed. Three forces are driving this shift. First, autonomous agents are increasingly the counterparty on both sides of a transaction, not just people i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom